Supporting Opioid Substitution Treatment and Hepatitis C Treatment in People Who Inject Drugs: A Strategy Toward Hepatitis C EliminationPremiere Date: Thursday, September 30, 2021
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, September 30, 2022
Note: Credit Is No Longer Available
|Mark S. Gold, MD
ASAM's Annual Lifetime Achievement John P. McGovern Award & Prize Winner
Adjunct Professor of Psychiatry
Washington University School of Medicine
St. Louis, MO
17th University of Florida Distinguished Alumni Professor
It has been hypothesized that opioid substitution treatment (OST) may increase engagement in hepatitis C virus (HCV) care among people who inject drugs (PWID). In the recent publication Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis, Grebely and colleagues conducted a systematic review of existing literature to evaluate the association between OST and HCV testing and treatment uptake, and to assess the association between OST and adherence, treatment completion, and sustained virologic response (SVR) following treatment among PWID.
In this installment of Research You Can Use, Dr. Gold will translate the data and provide his insights and application to clinical practice.
At the end of this CE activity, participants should be able to:
- Address disparities in HCV treatment initiation in underserved populations with limited access to specialists.
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, emergency medicine physicians, addiction specialists, harm reduction clinics, PAs, nurse practitioners, nurses, and pharmacists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning format: Enduring material
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gold has no disclosures to report.
Tony Graham, (peer reviewer) has no disclosures to report
Mae Ochoa, RPh (peer reviewer) has no disclosures to report
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).